Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Operating Expenses (2021 - 2025)

Senti Biosciences has reported Operating Expenses over the past 5 years, most recently at $18.7 million for Q4 2025.

  • Quarterly results put Operating Expenses at $18.7 million for Q4 2025, up 15.41% from a year ago — trailing twelve months through Dec 2025 was $68.8 million (up 12.72% YoY), and the annual figure for FY2025 was $68.8 million, up 12.72%.
  • Operating Expenses for Q4 2025 was $18.7 million at Senti Biosciences, up from $16.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for SNTI hit a ceiling of $44.2 million in Q3 2023 and a floor of $1178.0 in Q1 2021.
  • Median Operating Expenses over the past 5 years was $16.3 million (2023), compared with a mean of $16.4 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 1091750.59% in 2022 and later crashed 65.59% in 2024.
  • Senti Biosciences' Operating Expenses stood at $11.7 million in 2021, then skyrocketed by 44.31% to $16.9 million in 2022, then grew by 10.95% to $18.7 million in 2023, then fell by 13.54% to $16.2 million in 2024, then increased by 15.41% to $18.7 million in 2025.
  • The last three reported values for Operating Expenses were $18.7 million (Q4 2025), $16.9 million (Q3 2025), and $16.8 million (Q2 2025) per Business Quant data.